Resistance to tyrosine kinase inhibitors promotes renal cancer progression through MCPIP1 tumor-suppressor downregulation and c-Met activation

Tyrosine kinase inhibitors (TKIs) are the most commonly used targeted therapeutics in clear-cell renal cell carcinoma (ccRCC); however, drug resistance limits their utility and can lead to tumor “flare-up” and progression. In this study, we show that RCC resistance to sunitinib and sorafenib involve...

Descripción completa

Detalles Bibliográficos
Autores principales: Marona, Paulina, Górka, Judyta, Kwapisz, Oliwia, Jura, Jolanta, Rys, Janusz, Hoffman, Robert M., Miekus, Katarzyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500022/
https://www.ncbi.nlm.nih.gov/pubmed/36138026
http://dx.doi.org/10.1038/s41419-022-05251-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9500022/
https://www.ncbi.nlm.nih.gov/pubmed/36138026
http://dx.doi.org/10.1038/s41419-022-05251-4

Ejemplares similares